
BMS, BioNTech Ink Up-to-$11B Cancer Bispecific Antibody Collaboration
Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that could generate up to $11.1 billion for the German next- …